Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, OntarioDr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.
Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.
Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.
Disclosures
- Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics
Recent Contributions to PracticeUpdate:
- A Conservative, Medication-Based Approach Prevents Major Cardiovascular Events as Effectively as Invasive Procedures in Patients With Stable Ischemic Heart Disease
- Internet-Based Vestibular Rehabilitation for Adults With a Chronic Vestibular Syndrome
- Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction
- Association of Metabolically Healthy Overweight Phenotype With Abnormalities of Glucose Levels and Blood Pressure Among Chinese Adults
- Antithrombotic Treatment After CABG
- Colorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy
- Association of Treatment With Metformin vs Sulfonylurea With MACE Among Patients With Diabetes and Reduced Kidney Function
- A Report on E-Cigarette Use and Pulmonary Illness
- Use of Fenofibrate on Cardiovascular Outcomes in Statin Users With Metabolic Syndrome
- Ticagrelor ± Aspirin in High-Risk Patients After PCI